• 1. Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Department of Intensive Care Unit, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
CHEN Liping, Email: 47137417@qq.com
Export PDF Favorites Scan Get Citation

Objective To review the definition, incidence, risk factors, potential pathogenesis, biomarkers, and choice of follow-up treatment strategies of hyperprogressive disease (HPD).Method Domestic and international literatures were collected to summarize the research progress of HPD in patients with malignant tumors who treated with immune checkpoint inhibitors (ICIs).Results The research types of HPD were scattered, the sample size was limited, the definition standard was different, and there was lack of prospective validation studies. Therefore, the early warning assessment and molecular mechanism of HPD would become the next focus of the study of immunotherapy.Conclusion ICIs can greatly improve the survival time of some patients with advanced malignant tumor, although some patients have HPD during treatment, but the incidence is relatively low.